Crossmark

An assessment of the implications of distribution remuneration and taxation policies on the final prices of prescription medicines: evidence from 35 countries

Crossref DOI link: https://doi.org/10.1007/s10198-024-01706-x

Published Online: 2024-09-19

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Leon, Giovanny

Carbonel, Christophe

Rampuria, Aparajit

Rajpoot, Ravindra Singh

Joshi, Parth

Kanavos, Panos https://orcid.org/0000-0001-9518-3089
Funding

Funding for this research was provided by:

Novartis
License Information

Text and Data Mining valid from 2024-09-19

Version of Record valid from 2024-09-19
More Information

Article History

Received: 29 July 2023

Accepted: 1 July 2024

First Online: 19 September 2024

Declarations

:

: The study was funded through an unrestricted grant from Novartis to the Medical Technology Research Group, LSE Health, London School of Economics. The sponsor had no involvement in the design of the study or the drafting of the manuscript. The sponsor enabled access to the IQVIA MIDAS® database.

: Not applicable.

Document is current

Any future updates will be listed below